Full text
Earnings transcript
Read the complete earnings call transcript.
HIMS
Hims & Hers Health, Inc.
$19.14
-0.7
(-3.53%)
[ms_data_label text=’Delayed data’]
| Exchange: | NYSE |
| Market Cap: | 4.202B |
| Shares Outstanding: | 67.293M |
About The Company
| Sector: | Healthcare | |||||
| Industry: | Medical – Equipment & Services | |||||
| CEO: | Andrew Dudum | |||||
| Full Time Employees: | 1637 | |||||
| Address: |
| |||||
| Website: | https://www.forhims.com |
Hims & Hers Health, Inc. operates a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals. The company offers a range of health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supplement products, primarily focusing on wellness, sexual health and wellness, skincare, and hair care. The company’s curated non-prescription products include vitamin C, melatonin, biotin, and collagen protein supplements in the wellness category; moisturizer, serums, and face wash in the skincare category; condoms, climax delay spray and wipes, vibrators, and lubricants in the sexual health and wellness category; and shampoos, conditioners, scalp scrubs, and topical treatments, such as minoxidil in the hair care category. In addition, it offers medical consultation services, as well as health and wellness products through wholesale partners. The company is based in San Francisco, California.
Click to read more…
Revenue Segmentation
EPS
Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.
Earnings Call
AI summary
Key takeaways
Short, structured highlights from the call so you can focus on what matters.
Log in to continue
Log in to read the full transcript and AI-generated earnings summaries.
Login — it's freeIncome Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 872,000 | 1,476,514 | 2,347,637 |
| Gross Profit | 714,949 | 1,173,135 | 1,733,378 |
| EBITDA | -19,938 | 78,991 | 160,115 |
| Operating Income | -29,453 | 61,903 | 105,613 |
| Net Income | -23,546 | 126,038 | 128,365 |
(* All numbers are in thousands)
Balance Sheet
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total Assets | 441,186 | 707,539 | 2,154,705 |
| Total Liabilities | 97,157 | 230,823 | 1,613,777 |
| Total Stockholders Equity | 344,029 | 476,716 | 540,928 |
| Total Debt | 9,948 | 11,345 | 1,120,590 |
| Cash and Cash Equivalents | 96,663 | 220,584 | 228,616 |
(* All numbers are in thousands)
Cash Flow Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating Cash Flow | 73,483 | 251,084 | 300,006 |
| Capital Expenditure | -26,492 | -41,655 | -226,045 |
| Free Cash Flow | 46,991 | 209,429 | 73,961 |
| Net Income | -23,546 | 126,038 | 128,365 |
| Net Change in Cash | 49,891 | 123,921 | 7,176 |
(* All numbers are in thousands)
Analyst Estimates
| Fiscal Year | 2030 | Full Access | Full Access | Full Access | Full Access |
|---|---|---|---|---|---|
| Estimated Revenue (Low) | 4,005,537.485 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (High) | 5,260,106.766 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (Avg) | 4,629,850 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Low) | 1,731,245.315 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (High) | 2,273,486.449 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Avg) | 2,001,081.291 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Low) | 396,110.166 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (High) | 565,307.986 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Avg) | 480,308.819 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Low) | 2,694,651.092 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (High) | 3,538,639.320 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Avg) | 3,114,645.764 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Avg) | 1.860 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (High) | 2.190 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Low) | 1.530 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated Revenue) | 6 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated EPS) | 2 | Full Access | Full Access | Full Access | Full Access |
Log in to continue
Log in and subscribe to Full Access to see up to 5 years of analyst estimates.
Login — it's free(* All numbers are in thousands)
Current Key Metrics
Log in to continue
Log in to see all key valuation metrics and ratios for this symbol.
Login — it's freeForward P/E Ratios
Log in to continue
Log in with Full Access for forward P/E high/low estimates and the full multi-year table.
Login — it's freeSWOT Analysis
Strengths (preview)
- Strong Revenue Growth: Hims & Hers reported significant revenue increases in Q4 2024, as highlighted in the earnings call transcript, reflecting robust demand for their telehealth and personalized health solutions. This growth aligns with consistent positive performance metrics over the past year (perf1y), outperforming industry averages in the short term (industry_perf1y).
- Innovative Product Offerings: The company’s focus on expanding personalized healthcare solutions, as mentioned in the Q4 2024 earnings call, positions HIMS as a leader in the telehealth space. Their ability to innovate is supported by healthy gross profit margins (grossProfitMarginTTM), indicating efficient operations.
- Solid Financial Position: HIMS maintains a strong balance sheet with adequate cash and cash equivalents (cashAndCashEquivalents) and a manageable debt-to-equity ratio (debtToEquityRatioTTM). This financial stability supports ongoing investments in growth initiatives without excessive leverage.
- Positive Earnings Performance: The company achieved better-than-expected net income and EPS in Q4 2024 (earnings call summary), demonstrating operational efficiency and profitability despite competitive pressures, with a favorable price-to-earnings ratio (priceToEarningsRatioTTM) compared to industry averages (industry_avg_priceToEarningsRatioTTM).
Log in with Full Access for Weaknesses, Opportunities, Threats, and the complete SWOT.
At what price to buy it? -
Intrinsic Value Calculator
Based on current fundamentals and analyst forecasts, MARKETSnap estimates HIMS intrinsic value between $13.01 – $18.86 per share. This depends on revenue growth, margins, and discount rate.
This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.
Common questions about HIMS valuation
Is Hims & Hers Health, Inc. (HIMS) overvalued or undervalued right now?
MARKETSnap estimates intrinsic value for Hims & Hers Health, Inc. (HIMS) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.
Is HIMS a buy, hold, or sell for long-term investors?
MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether HIMS trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.
What is HIMS’s P/E ratio?
You can see HIMS’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.
How is intrinsic value calculated for HIMS?
MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.
Is HIMS a good long-term investment?
Whether HIMS fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.
HIMS
1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.
[ms_data_label text="Daily snapshot"]
-3.53
Trading Metrics:
| Open: | [ms_cell_or_dash table='trading_quote' column='open'] | Previous Close: | [ms_cell_or_dash table='trading_quote' column='previousClose'] | |
| Day Low: | [ms_cell_or_dash table='trading_quote' column='dayLow'] | Day High: | [ms_cell_or_dash table='trading_quote' column='dayHigh'] | |
| Year Low: | 13.74 | Year High: | 70.43 | |
| Price Avg 50: | 21.15 | Price Avg 200: | 39.79 | |
| Volume: | 21.854M | Average Volume: | 39.528M |
Log in to continue
Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.
Login — it's freeHIMS full analysis
Hey everyone, welcome back to the channel! Today, we’re diving deep into a company that’s been making waves in the telehealth space, Hims & Hers Health, ticker symbol HIMS. If you’ve been curious about this stock, especially with all the recent buzz around their partnership with Novo Nordisk and a massive 50% surge in their share price, you’re in the right place. We’re going to break down everything from their financials to their valuation, recent performance, and more. So, grab…
